Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins.
Alice SosicIrene SacconeCaterina CarraroThomas KenderdineElia GambaGiuseppe CaliendoAngela CorvinoPaola Di VaioFerdinando FiorinoElisa MagliElisa PerissuttiVincenzo SantagadaBeatrice SeverinoValentina SpadaDan FabrisFrancesco FrecenteseBarbara GattoPublished in: Bioconjugate chemistry (2018)
The HIV-1 nucleocapsid (NC) protein represents an excellent molecular target for the development of anti-retrovirals by virtue of its well-characterized chaperone activities, which play pivotal roles in essential steps of the viral life cycle. Our ongoing search for candidates able to impair NC binding/annealing activities led to the identification of peptidyl-anthraquinones as a promising class of nucleic acid ligands. Seeking to elucidate the inhibition determinants and increase the potency of this class of compounds, we have now explored the effects of chirality in the linker connecting the planar nucleus to the basic side chains. We show here that the non-natural linker configuration imparted unexpected TAR RNA targeting properties to the 2,6-peptidyl-anthraquinones and significantly enhanced their potency. Even if the new compounds were able to interact directly with the NC protein, they manifested a consistently higher affinity for the TAR RNA substrate and their TAR-binding properties mirrored their ability to interfere with NC-TAR interactions. Based on these findings, we propose that the viral Tat protein, sharing the same RNA substrate but acting in distinct phases of the viral life cycle, constitutes an additional druggable target for this class of peptidyl-anthraquinones. The inhibition of Tat-TAR interaction for the test compounds correlated again with their TAR-binding properties, while simultaneously failing to demonstrate any direct Tat-binding capabilities. These considerations highlighted the importance of TAR RNA in the elucidation of their inhibition mechanism, rather than direct protein inhibition. We have therefore identified anti-TAR compounds with dual in vitro inhibitory activity on different viral proteins, demonstrating that it is possible to develop multitarget compounds capable of interfering with processes mediated by the interactions of this essential RNA domain of HIV-1 genome with NC and Tat proteins.
Keyphrases
- nucleic acid
- life cycle
- binding protein
- antiretroviral therapy
- hiv infected
- sars cov
- hiv positive
- hiv testing
- human immunodeficiency virus
- amino acid
- dna binding
- hiv aids
- protein protein
- men who have sex with men
- healthcare
- mental health
- gene expression
- coronavirus disease
- drug delivery
- mass spectrometry
- oxidative stress
- single molecule
- respiratory syndrome coronavirus